EVFM Evofem Biosciences has a big upcoming catalyst:
Its Phase 3 clinical trial evaluating Phexxi for the prevention of chlamydia and gonorrhea in women is on track to report top-line data from this landmark trial in mid-October, so we are one week away from results!
Positive study outcomes would enable potential U.S. approval for prevention of these sexually...